Belite Bio Reports Q3 2026 Financial Results and Clinical Progress for Tinlarebant
Belite Bio (BLTE) reported its third-quarter 2026 financial results, highlighting a GAAP net loss of $30.3 million compared to $21.7 million in the prior year. The increase in expenses was driven by higher research and development costs totaling $15.5 million, primarily due to manufacturing and consulting fees, as well as increased selling, general, and administrative expenses. On the clinical front, the company reported positive data from its DRAGON trial, showing a 35.7% reduction in retinal lesion growth rates compared to placebo. With the PHOENIX Phase 3 trial enrollment complete and an FDA PDUFA target action date of February 12, 2027, for Tinlarebant in Stargardt disease, Belite Bio is positioning itself for potential commercialization. The company maintains a strong liquidity position with $774 million in cash, cash equivalents, and U.S. Treasury bills.
Tickers: $BLTE
Topics: clinical trial results earnings report net loss R&D expenses